NY State Senate Bill S649A

Archive: Last Bill Status Via A2030 - Signed by Governor

Introduced
In Committee
On Floor Calendar
- Passed Senate
- Passed Assembly
Delivered to Governor
Signed by Governor

Your Voice

Please enter your contact information

First Name *

Last Name *

Email Address *

A valid email address is required.

Home address search or enter your address manually *

Home address is used to determine the senate district in which you reside. Your support or opposition to this bill is then shared immediately with the senator who represents you.

Optional services from the NY State Senate:

Create an account. An account allows you to officially support or oppose key legislation, sign petitions with a single click, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.

Include a custom message for your Senator? (Optional)

Enter a message to your senator. Many New Yorkers use this to share the reasoning behind their support or opposition to the bill. Others might share a personal anecdote about how the bill would affect them or people they care about.

Leave this field blank

Actions

view actions (13)

	Assembly Actions - Lowercase Senate Actions - UPPERCASE
Dec 22, 2021	signed chap.720
Dec 10, 2021	delivered to governor
Jun 03, 2021	returned to assembly passed senate 3rd reading cal.1294 substituted for s649a
Jun 03, 2021	substituted by a2030
May 26, 2021	ordered to third reading cal.1294 committee discharged and committed to rules
May 11, 2021	reported and committed to finance
Feb 08, 2021	print number 649a
Feb 08, 2021	amend and recommit to health
Jan 06, 2021	referred to health

Votes

view votes

Jun 3, 2021 - floor Vote

A2030

floor

Aye

Nay

Absent

Excused

Abstained

May 26, 2021 - Rules committee Vote

S649A

committee

Aye

Nay

Aye with Reservations

Absent

Excused

Abstained

May 11, 2021 - Health committee Vote

S649A

committee

Aye

Nay

Aye with Reservations

Absent

Excused

Abstained

Bill Amendments

Original

A (Active)

Original

A (Active)

S649 - Details

See Assembly Version of this Bill:: A2030
Law Section:: Social Services Law
Laws Affected:: Amd §§365-a & 364-j, Soc Serv L; amd §273, Pub Health L
Versions Introduced in 2019-2020 Legislative Session:: S7699, A9634

S649 - Summary

Relates to medication assisted treatment for substance abuse disorders; prohibits prior authorization.

S649 - Sponsor Memo

 
BILL NUMBER: S649

SPONSOR: HARCKHAM
 
TITLE OF BILL:

An act to amend the social services law and the public health law, in
relation to medication for the treatment of substance use disorders

 
PURPOSE:

This legislation will expand access to medications that treat substance
use disorders.

 
SUMMARY OF SPECIFIC PROVISIONS:

Section one amends subdivision 2 of section 365-a of the social services
law by adding a new paragraph (gg)

Section two amends subdivision 26-b of section 364-j of the social
services law.

Section three amends subdivision 10 of section 273 of the public health
law.

Section four sets the effective date.

 
JUSTIFICATION:

Medication assisted treatment, or MAT, is an evidence based treatment
method that uses FDA approved medications to help an individual overcome
a substance use disorder. Medications such as methadone, buprenorphine
and naltrexone have all been used successfully and more treatment
providers are turning to this approach given its ability to reduce and
block cravings, ease withdrawal symptoms and otherwise enable an indi-
vidual to reach recovery more easily.

However, medications used in MAT programs are not interchangeable and
each patient may respond differently, therefore it is imperative that
this choice be left to the patient and their doctor to determine the
appropriate medication. Under current law, individuals under Medicaid
are not given the opportunity to access all forms of medication assisted
treatment and may be limited to one specific type. This legislation
would allow individuals under Medicaid the ability to access whichever
MAT medication is most beneficial to them and their needs, without
utilization control, mandated prior authorization, or lifetime limits.

 
LEGISLATIVE HISTORY:

2020: S7699 Third reading; same as referred to ways and means

 
FISCAL IMPLICATIONS:

Undetermined.

 
EFFECTIVE DATE:
This act shall take effect in 90 days.

S649 - Bill Text download pdf

 
                     S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
                                    649
 
                        2021-2022 Regular Sessions
 
                             I N  S E N A T E
 
                                (PREFILED)
 
                              January 6, 2021
                                ___________
 
 Introduced  by Sen. HARCKHAM -- read twice and ordered printed, and when
   printed to be committed to the Committee on Health
 
 AN ACT to amend the social services law and the public  health  law,  in
   relation to medication for the treatment of substance use disorders

   THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
   Section 1. Subdivision 2 of section 365-a of the social  services  law
 is amended by adding a new paragraph (gg) to read as follows:
   (GG)  ALL  BUPRENORPHINE PRODUCTS, METHADONE OR LONG ACTING INJECTABLE
 NALTREXONE FOR DETOXIFICATION OR MAINTENANCE TREATMENT  OF  A  SUBSTANCE
 USE DISORDER PRESCRIBED ACCORDING TO GENERALLY ACCEPTED NATIONAL PROFES-
 SIONAL  GUIDELINES  FOR THE TREATMENT OF A SUBSTANCE USE DISORDER.  SUCH
 MEDICATION ASSISTED TREATMENT SHALL NOT BE SUBJECT TO ANY PRIOR AUTHORI-
 ZATION MANDATE.
   § 2. Subdivision 26-b of section 364-j of the social services law,  as
 added  by  section  4  of  part  B of chapter 69 of the laws of 2016, is
 amended to read as follows:
   26-b. Managed care providers shall not require prior authorization for
 [an initial or renewal  prescription  for  buprenorphine  or  injectable
 naltrexone   for  detoxification  or  maintenance  treatment  of  opioid
 addiction unless the prescription is for a non-preferred  or  non-formu-
 lary  form of the drug or as otherwise required by section 1927(k)(6) of
 the Social Security Act] ANY BUPRENORPHINE PRODUCTS, METHADONE  OR  LONG
 ACTING INJECTABLE NALTREXONE FOR DETOXIFICATION OR MAINTENANCE TREATMENT
 OF  A  SUBSTANCE USE DISORDER PRESCRIBED ACCORDING TO GENERALLY ACCEPTED
 NATIONAL PROFESSIONAL GUIDELINES FOR THE TREATMENT OF  A  SUBSTANCE  USE
 DISORDER.
   §  3. Subdivision 10 of section 273 of the public health law, as added
 by section 5 of part B of chapter 69 of the laws of 2016, is amended  to
 read as follows:
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets

                       [ ] is old law to be omitted.
                                                            LBD00371-01-1

 S. 649                              2
 
   10.  Prior  authorization  shall  not  be  required for [an initial or
 renewal prescription for  buprenorphine  or  injectable  naltrexone  for
 detoxification  or  maintenance treatment of opioid addiction unless the
 prescription is for a non-preferred or non-formulary form of  such  drug
 as  otherwise required by section 1927(k)(6) of the Social Security Act]
 ANY BUPRENORPHINE PRODUCTS, METHADONE OR LONG ACTING INJECTABLE NALTREX-
 ONE FOR DETOXIFICATION OR  MAINTENANCE  TREATMENT  OF  A  SUBSTANCE  USE
 DISORDER  PRESCRIBED  ACCORDING  TO  GENERALLY ACCEPTED NATIONAL PROFES-
 SIONAL GUIDELINES FOR THE TREATMENT OF A SUBSTANCE USE DISORDER.
   § 4. This act shall take effect on the ninetieth day  after  it  shall
 have become a law; provided, however, that the amendments to subdivision
 26-b  of section 364-j of the social services law made by section two of
 this act shall not affect the repeal  of  such  section,  and  shall  be
 deemed repealed therewith.

Co-Sponsors

S649A (ACTIVE) - Details

See Assembly Version of this Bill:: A2030
Law Section:: Social Services Law
Laws Affected:: Amd §§365-a & 364-j, Soc Serv L; amd §273, Pub Health L
Versions Introduced in 2019-2020 Legislative Session:: S7699, A9634

S649A (ACTIVE) - Summary

Relates to medication assisted treatment for substance abuse disorders; prohibits prior authorization.

S649A (ACTIVE) - Sponsor Memo

 
BILL NUMBER: S649A

SPONSOR: HARCKHAM
 
TITLE OF BILL:

An act to amend the social services law and the public health law, in
relation to medication for the treatment of substance use disorders

 
PURPOSE:

This legislation will expand access to medications that treat substance
use disorders.

 
SUMMARY OF SPECIFIC PROVISIONS:

Section one amends subdivision 2 of section 365-a of the social services
law by adding a new paragraph (gg)

Section two amends subdivision 26-b of section 364-j of the social
services law. Section three amends subdivision 10 of section 273 of the
public health law. Section four sets the effective date.

 
JUSTIFICATION:

Medication assisted treatment, or MAT, is an evidence-based treatment
method that uses FDA approved medications to help an individual overcome
a substance use disorder. Medications such as methadone, buprenorphine
and naltrexone have all been used successfully and more treatment
providers are turning to this approach given its ability to reduce and
block cravings, ease withdrawal symptoms and otherwise enable an indi-
vidual to reach recovery more easily. However, medications used in MAT
programs are not interchangeable and each patient may respond different-
ly, therefore it is imperative that this choice be left to the patient
and their doctor to determine the appropriate medication. Under current
law, individuals under Medicaid are not given the opportunity to access
all forms of medication assisted treatment and may be limited to one
specific type. This legislation would allow individuals under Medicaid
the ability to access whichever MAT medication is most beneficial to
them and their needs, without utilization control, mandated prior
authorization, or lifetime limits.

 
LEGISLATIVE HISTORY:

2019: A.7246-B/S.5935-A - Vetoed

 
FISCAL IMPLICATIONS:

Undetermined.

 
EFFECTIVE DATE:
This act shall take effect in 90 days.

S649A (ACTIVE) - Bill Text download pdf

 
                     S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
                                  649--A
 
                        2021-2022 Regular Sessions
 
                             I N  S E N A T E
 
                                (PREFILED)
 
                              January 6, 2021
                                ___________
 
 Introduced  by Sen. HARCKHAM -- read twice and ordered printed, and when
   printed to be committed  to  the  Committee  on  Health  --  committee
   discharged, bill amended, ordered reprinted as amended and recommitted
   to said committee

 AN  ACT  to  amend the social services law and the public health law, in
   relation to medication for the treatment of substance use disorders
 
   THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND  ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
   Section  1.  Subdivision 2 of section 365-a of the social services law
 is amended by adding a new paragraph (gg) to read as follows:
   (GG) ALL BUPRENORPHINE PRODUCTS, METHADONE OR LONG  ACTING  INJECTABLE
 NALTREXONE  FOR  DETOXIFICATION  OR MAINTENANCE TREATMENT OF A SUBSTANCE
 USE DISORDER PRESCRIBED ACCORDING TO GENERALLY ACCEPTED NATIONAL PROFES-
 SIONAL GUIDELINES FOR THE TREATMENT OF A SUBSTANCE USE DISORDER.    SUCH
 MEDICATION ASSISTED TREATMENT SHALL NOT BE SUBJECT TO ANY PRIOR AUTHORI-
 ZATION MANDATE.
   §  2. Subdivision 26-b of section 364-j of the social services law, as
 added by section 4 of part B of chapter 69  of  the  laws  of  2016,  is
 amended to read as follows:
   26-b. Managed care providers shall not require prior authorization for
 [an  initial  or  renewal  prescription  for buprenorphine or injectable
 naltrexone  for  detoxification  or  maintenance  treatment  of   opioid
 addiction  unless  the prescription is for a non-preferred or non-formu-
 lary form of the drug or as otherwise required by section 1927(k)(6)  of
 the  Social  Security Act] ANY BUPRENORPHINE PRODUCTS, METHADONE OR LONG
 ACTING INJECTABLE NALTREXONE FOR DETOXIFICATION OR MAINTENANCE TREATMENT
 OF A SUBSTANCE USE DISORDER PRESCRIBED ACCORDING TO  GENERALLY  ACCEPTED
 NATIONAL  PROFESSIONAL  GUIDELINES  FOR THE TREATMENT OF A SUBSTANCE USE
 DISORDER.
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                       [ ] is old law to be omitted.

                                                            LBD00371-03-1

 S. 649--A                           2
 
   § 3. Subdivision 10 of section  273  of  the  public  health  law,  as
 amended  by  section  7 of part GG of chapter 56 of the laws of 2020, is
 amended to read as follows:
   10.  Prior  authorization  shall  not  be  required for [an initial or
 renewal prescription for  buprenorphine  or  injectable  naltrexone  for
 detoxification  or  maintenance treatment of opioid addiction unless the
 prescription is for a non-preferred or non-formulary form of  such  drug
 as  otherwise required by section 1927(k)(6) of the Social Security Act.
 Further, prior authorization shall not be required  for]  ANY  BUPRENOR-
 PHINE PRODUCTS, methadone, [when used for opioid use disorder and admin-
 istered  or  dispensed  in  an  opioid treatment program] OR LONG ACTING
 INJECTABLE NALTREXONE FOR DETOXIFICATION OR MAINTENANCE TREATMENT  OF  A
 SUBSTANCE  USE  DISORDER  PRESCRIBED  ACCORDING  TO  GENERALLY  ACCEPTED
 NATIONAL PROFESSIONAL GUIDELINES FOR THE TREATMENT OF  A  SUBSTANCE  USE
 DISORDER.
   §  4.  This  act shall take effect on the ninetieth day after it shall
 have become a law; provided, however, that the amendments to subdivision
 26-b of section 364-j of the social services law made by section two  of
 this  act  shall  not  affect  the  repeal of such section, and shall be
 deemed repealed therewith.

Comments

Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.

Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.

The New York State Senate

senate Bill S649A

Sponsored By

Archive: Last Bill Status Via A2030 - Signed by Governor

Your Voice

Actions

Votes

Jun 3, 2021 - floor Vote

Floor Vote: Jun 3, 2021

May 26, 2021 - Rules committee Vote

Rules Committee Vote: May 26, 2021

May 11, 2021 - Health committee Vote

Health Committee Vote: May 11, 2021

Bill Amendments

S649 - Details

S649 - Summary

S649 - Sponsor Memo

S649 - Bill Text download pdf

Co-Sponsors

S649A (ACTIVE) - Details

S649A (ACTIVE) - Summary

S649A (ACTIVE) - Sponsor Memo

S649A (ACTIVE) - Bill Text download pdf

Comments

senate Bill S649A

Share this bill

Sponsored By

Pete Harckham

Archive: Last Bill Status Via A2030 - Signed by Governor

Your Voice

Actions

Votes

Jun 3, 2021 - floor Vote

Floor Vote: Jun 3, 2021

May 26, 2021 - Rules committee Vote

Rules Committee Vote: May 26, 2021

May 11, 2021 - Health committee Vote

Health Committee Vote: May 11, 2021

Bill Amendments

S649 - Details

S649 - Summary

S649 - Sponsor Memo

S649 - Bill Text download pdf

Co-Sponsors

Fred Akshar

Samra G. Brouk

Robert Jackson

S649A (ACTIVE) - Details

S649A (ACTIVE) - Summary

S649A (ACTIVE) - Sponsor Memo

S649A (ACTIVE) - Bill Text download pdf

Comments